Reacción a "Reactions to the approval of the Omicron vaccine in the UK"

This is Moderna's bivalent vaccine, which targets two spicule proteins: the original Wuhan virus and Omicron (the BA.1 lineage). Updates of the vaccine are welcome news and, in principle, will generate more potent and broader immunity than the current univalent format.

Previous studies even suggest a good response of this new vaccine against the most prevalent lineage, currently BA.5. However, the development of new variants by the virus is always ahead of vaccine updates, and it is possible that by the time vaccination begins, a new lineage will have emerged.